FOXM1 expression level has been shown in numerous types of human cancer to be dose-dependently correlated with tumor progression starting from cancer predisposition and initiation (Gemenetzidis et al., 2010; Jia et al., 2010; Teh et al., 2010), early premalignancy and progression (Gemenetzidis et al., 2009; Nakamura et al., 2010; Waseem et al., 2010; Huynh et al., 2011) to metastatic invasion (reviewed in Wierstra and Alves, 2007). This evidence concerns the gene FOXM1 and cancer.